Progress of Research on Therapeutic Drug Monitoring in Treatment of Novel Biological Agents for Inflammatory Bowel Disease
10.3969/j.issn.1008-7125.2022.11.006
- Author:
Fengfeng YAN
1
;
Hongjie ZHANG
1
;
Ying XU
1
Author Information
1. Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University
- Publication Type:Journal Article
- Keywords:
Inflammatory Bowel Disease;
Therapeutic Drug Monitoring;
Therapy;
Ustekinumab;
Vedolizumab
- From:
Chinese Journal of Gastroenterology
2022;27(11):680-685
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease, and its treatment includes traditional medicines and biological agents. Therapeutic drug monitoring is an important tool to optimize the treatment of biological agents. Therapeutic drug monitoring of tumor necrosis factor inhibitors has been used to guide the clinical decision ⁃ making. However, the value of therapeutic drug monitoring of novel biological agents (vedolizumab and ustekinumab) in IBD remains unclear. This article summarized the pharmacokinetics, drug concentration and treatment outcome, optimization of the novel biological agents in the treatment of IBD.
